{"entity":{"id":"nct06592417","kind":"trial","name":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.","summary":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors. ClinicalTrials.gov record last updated 2024-09-19: recruiting. Enrollment is planned at 140 participants. Primary completion is estimated at 2026-05-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06592417","url":"https://clinicaltrials.gov/study/NCT06592417"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["jskn016"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2024-09-19: recruiting. Enrollment is planned at 140 participants. Primary completion is estimated at 2026-05-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06592417","phase":"1","setting":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","started":"2024-04-30","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06592417/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"}]}}